JOHNSON & JOHNSON JNJ

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $260.31
Market Cap $630.96B
P/E Ratio 23.60
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑6.0% YoY
$94.19B
3-Yr CAGR: -0.3%
Net Income ↑90.6% YoY
$26.80B
Net Margin: 28.5%
Free Cash Flow ↓-0.7% YoY
$19.70B
FCF Yield: 3.12%
EPS (Diluted) ↑90.5% YoY
$11.03
Basic: $11.13
Return on Equity Efficiency
32.9%
ROA: 13.5%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (JNJ)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $18,106.0M $12,211.6M $15,409.0M $5.48 $19,279.0M $15,816.0M
FY 2017 $76,450.0M +322.2% $51,096.0M $1,300.0M -91.6% $0.47 -91.4% $21,056.0M $17,777.0M +12.4%
FY 2018 $81,581.0M +6.7% $54,490.0M $15,297.0M +1,076.7% $5.61 +1,093.6% $22,201.0M $18,531.0M +4.2%
FY 2019 $82,059.0M +0.6% $54,503.0M $15,119.0M -1.2% $5.63 +0.4% $23,416.0M $19,918.0M +7.5%
FY 2020 $82,584.0M +0.6% $54,157.0M $14,714.0M -2.7% $5.51 -2.1% $23,536.0M $20,189.0M +1.4%
FY 2021 $93,775.0M +13.6% $63,920.0M $20,878.0M +41.9% $7.81 +41.7% $23,410.0M $19,758.0M -2.1%
FY 2022 $94,943.0M +1.2% $64,034.1M $20,878.0M 0.0% $7.81 0.0% $23,410.0M $19,758.0M 0.0%
FY 2023 $85,159.0M -10.3% $58,606.0M $35,153.0M +68.4% $5.20 -33.4% $22,791.0M $18,248.0M -7.6%
FY 2024 $88,821.0M +4.3% $61,350.0M $14,066.0M -60.0% $5.79 +11.3% $24,266.0M $19,842.0M +8.7%
FY 2025 $94,193.0M +6.0% $63,937.0M $26,804.0M +90.6% $11.03 +90.5% $24,530.0M $19,698.0M -0.7%
$

Valuation

Market Price $260.31
Market Cap $630.96B
Enterprise Value $652.68B
P/E Ratio 23.60
P/B Ratio 7.68
FCF Yield 3.12%
Dividend Yield N/A
Shares Outstanding 2,407,217,000
%

Profitability & Margins

Gross Margin 67.88%
Operating Margin 7.65%
Net Margin 28.46%
Return on Equity (ROE) 32.87%
Return on Assets (ROA) 13.46%
Asset Turnover 0.47x
Revenue 3-Yr CAGR -0.26%
🛡️

Financial Health & Liquidity

Current Ratio 0.48
Cash Ratio 2.29
Debt / Equity 0.508
Debt / Assets 0.208
Cash & Equivalents $19.71B
Total Debt $41.44B
Book Value / Share $33.87
💧

Cash Flow Efficiency

Operating Cash Flow $24.53B
Capital Expenditures (CapEx) $4.83B
Free Cash Flow $19.70B
OCF / Revenue 26.04%
FCF / Revenue 20.91%
FCF 3-Yr CAGR -0.10%
🏷️

Per Share Metrics

EPS (Diluted) $11.03
EPS (Basic) $11.13
Dividends / Share N/A
Book Value / Share $33.87
EPS YoY Growth 90.50%
🏛️

Balance Sheet (FY 2025)

Total Assets $199.21B
Total Liabilities $117.67B
Stockholders' Equity $81.54B
Current Assets $4.15B
Current Liabilities $8.59B